At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 19 enrolled
Drug / intervention
ZD6474 (vandetanib)drug
Likely dose
ZD6474 (vandetanib) 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open-Label Study To Assess The Efficacy and Tolerability of ZD6474 (ZACTIMA™ ) 100 mg Monotherapy In Subjects With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
In Brief
A Phase 2 clinical trial evaluating ZD6474 (vandetanib) for Thyroid Cancer. Completed, enrolled 19 participants across 9 sites in 8 countries.
Detailed Summary
This will be a Phase II, open label study to establish the effect of once-daily oral doses of ZD6474 100mg in subjects with locally advanced or metastatic hereditary medullary thyroid cancer in whom no standard therapeutic option is available.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThyroid Cancer
CountriesAustralia, Canada, Italy, Netherlands, Romania, Spain, Switzerland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2006
Enrollment StartAug 2006
Primary CompletionJan 2008
Study CompletionMay 2014
TodayJul 2026
First PostedAug 1, 2006
Enrollment StartAug 1, 2006
Primary CompletionJan 1, 2008
Study CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 19.9 years ago
Interventions
ZD6474 (vandetanib)drug
100 mg once daily oral tablet